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Neuroinﬂammation has received increased attention as a target for putative neuropro-
tective therapies in Parkinson’s Disease (PD). Two prototypic pro-inﬂammatory cytokines
interleukin-1β (IL-1) and tumor necrosis factor-α (TNF) have been implicated as main
effectors of the functional consequences of neuroinﬂammation on neurodegeneration in
PD models. In this review, we describe that the functional interaction between these
cytokines in the brain differs from the periphery (e.g., their expression is not induced by
each other) and present data showing predominantly a toxic effect of these cytokines
when expressed at high doses and for a sustained period of time in the substantia nigra
pars compacta (SN). In addition, we highlight opposite evidence showing protective effects
of these two main cytokines when conditions of duration, amount of expression or state
of activation of the target or neighboring cells are changed. Furthermore, we discuss these
results in the frame of previous disappointing results from anti-TNF-α clinical trials against
Multiple Sclerosis, another neurodegenerative disease with a clear neuroinﬂammatory
component. In conclusion, we hypothesize that the available evidence suggests that the
duration and dose of IL-1β or TNF-α expression is crucial to predict their functional effect
on the SN. Since these parameters are not amenable for measurement in the SN of PD
patients, we call for an in-depth analysis to identify downstream mediators that could be
common to the toxic (and not the protective) effects of these cytokines in the SN. This
strategy could spare the possible neuroprotective effect of these cytokines operative in
the patient at the time of treatment, increasing the probability of efﬁcacy in a clinical
setting. Alternatively, receptor-speciﬁc agonists or antagonists could also provide a way
to circumvent undesired effects of general anti-inﬂammatory or speciﬁc anti-IL-1β orTNF-α
therapies against PD.
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PARKINSON’S DISEASE AND NEUROINFLAMMATION
Parkinson’s Disease (PD) is a neurodegenerative disorder affect-
ing over 1% of the population above 65 years of age (Lesage
and Brice, 2009; Obeso et al., 2010; Coelho and Ferreira, 2012).
Its cardinal symptoms are bradykinesia (slowness of movement),
tremor, rigidity, and postural imbalance (Lesage and Brice, 2009;
Obeso et al., 2010; Coelho and Ferreira, 2012). Gait disturbances,
swallowing and speech problems, autonomic dysfunctions, and
cognitive decline can also be present in PD patients (Obeso et al.,
2010). Dopaminergic neurons in the substantia nigra pars com-
pacta (SN) projecting to the striatum are the main, but not the
only neurons degenerating in PD. The death of these dopaminer-
gic neurons causes the classical motor symptoms of these patients.
When patients suffer motor symptoms, over 60% of all dopamine
neurons within speciﬁc regions of the basal ganglia may have been
lost (Bernheimer et al., 1973). Current therapies are focused on
the restoration of dopamine levels in the striatum by the admin-
istration of dopamine precursors, dopamine agonists, or selective
inhibitors of dopamine uptake, among other pharmacological
strategies (Obeso et al., 2010). Another therapeutic approach is
the implantation of electrodes to reduce the overexcitation of spe-
ciﬁc brain areas such as the subthalamic nucleus (Okun, 2012).
However, no therapy is available that can slow down or halt the
progression of PD or regenerate the affected brain regions. The
lack of improved therapies is attributable to the incomplete knowl-
edge available on the etiology and physiopathology of the disease.
The delayed diagnosis of PD also adds difﬁculty in designing new
therapeutic avenues.
Although a load of valuable information has been obtained
during the last years, the etiology of not more than 5% of PD
cases has been revealed to be caused by genetic defects (Smith
et al., 2012). Environmental factors such as pesticides have also
been shown to trigger idiopathic PD (Wirdefeldt et al., 2011). In
addition, impairment of genes involved in detoxiﬁcation can con-
tribute to the risk to develop PD, as some polymorphisms and
mutations that increase or reduce the activity of the paraoxonase
1 gene could be reducing or increasing the risk for PD, respectively
(Benmoyal-Segal et al., 2005; Belin et al., 2012).
In parallel to an intense effort to unravel the etiology of PD,
increasing evidence is now available on the physiopathology of this
illness. It is foreseen that the understanding of the pathological
process of neurodegeneration and the subsequent identiﬁcation
of the molecules mediating this process will allow the detection
of new therapeutic targets. These novel targets should enable
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the design of disease-modifying therapies, slowing down or halt-
ing disease progression. The involvement of neuroinﬂammation
in the pathogenesis of PD in patients is supported by several
reports that anti-inﬂammatory medication use is associated with a
reduction in the risk of PD (Chen et al., 2005). Moreover, inﬂam-
mation biomarkers, like high-sensitivity C-reactive protein and
interleukin-6 (IL-6) were found upregulated in human patients
(Chen et al., 2008; Soreq et al., 2008; Song et al., 2011).
An ubiquitous physiopathological feature of the degenerat-
ing SN in animal models and PD patients is the presence of
robust microglial activation in that brain region. Not so long ago,
microglial activation has been regarded as a physiological conse-
quence of neuronal death, whose function was solely to remove
neuronal debris. This vision was wrong. Microglial activation can
lead to toxic but also protective effects on the on-going neurode-
generating neurons of the SN (reviewed in Roca et al., 2011). This
review will be focused on the functional consequences of two pro-
totypical microglial-derived cytokines [IL-1β and TNF-α] on PD
physiopathology.
PD AND MICROGLIAL ACTIVATION
Microglial cells are the resident macrophages of the brain (Perry
et al., 2010). They are main mediators of the innate immune
response and account for ca. 10% of all brain cells (Perry
et al., 2010). Upon changes in their surrounding environment,
microglial cells become activated, changing their morphology
and secreting a variety of molecules with functional conse-
quences in the central nervous system (CNS). The activation
of microglial cells in the degenerating SN in PD is ubiquitous.
It has been found in mice, rats, and monkeys models of PD
based on neurotoxins such as 6-hydroxydopamine (6-OHDA),
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) pesticides
such as rotenone or alpha-synuclein overexpression (reviewed in
Roca et al., 2011). In addition, robust microglial activation has
been found in the SN in post-mortem samples and by imaging
techniques in PD patients (reviewed in Roca et al., 2011).
Until recently, microglial activation was associated with a pro-
inﬂammatory environment. Our group has shown that microglial
activation during neurodegeneration in the SN leads to pro-
inﬂammatory cytokine transcription but not translation in these
cells (Depino et al., 2003). This “atypical” activation of microglial
cells, associated with neurodegeneration but not with inﬂam-
mation was in line with previous observations in prion and
Alzheimer’s disease (AD; Perry et al., 2002). From these works,
it became clear that microglial activation does not always lead
to an inﬂammatory response. On the other hand, an inﬂam-
matory response always involves microglial activation. Therefore,
microglial activation is a necessary but not a sufﬁcient feature of
neuroinﬂammation.
As stated above, activated microglia will secrete a plethora of
molecules with functional consequences for their environment
in general, and the dying neurons in particular. It is important to
highlight that the functional consequences of microglial activation
will depend on the array of molecules they secrete. This review will
focus on the functional role on the degenerating SN of two proto-
typic, microglial secreted pro-inﬂammatory cytokines, IL-1β and
TNF-α. These two cytokines are potent mediators of microglial
function and key to modulate the complex network of interactions
of microglial-secreted molecules. Provided that microglial activa-
tion is ubiquitous and that these two cytokine exert such a potent
inﬂuence on the ﬁnal functional outcome of microglial activation,
they have been proposed as possible targets to be used in neuropro-
tective, disease-modifying therapies against PD. In the following
review, we will discuss the role of these molecules on neuronal
death in the SN, their interaction (which has distinct features in
the brain compared with the periphery) and the parameters that
will affect their ﬁnal effect on the dopaminergic neurons.
Most of the available evidence leads to conclude that IL-1β and
TNF-α are toxic for the dopaminergic neurons of the SN. How-
ever, completely opposite results have also been obtained, showing
IL-1β and TNF-α-derived neuroprotective effects. Several groups
including ours, have found that the ﬁnal effect of these cytokines
on dopaminergic cell viability depends on many variables such as
concentration, duration of expression and state of activation of
the target or neighboring cells (Depino et al., 2003; Ferrari et al.,
2004, 2006).
Before presenting and discussing the data that lead to these
conclusions, a general overview of each cytokine is presented, nec-
essary for the full understanding of the biological effects of these
cytokines on neurodegeneration.
IL-1β – GENERALITIES
IL-1β was ﬁrst described by around 1943 as an agent coming from
rabbit peritoneal cells. Its ﬁrst biological property to be discovered
was to produce fever, and therefore was termed endogenous pyro-
gen (Dinarello, 1996). IL-1β is a pro-inﬂammatory cytokine that
participates in several neuroimmunological and neurophysiolog-
ical activities in the CNS. IL-1 family comprises eleven members,
among which IL-1α and IL-1β are the best studied. Both proteins
have a 25% of sequence similarity at the protein level despite being
products of different genes (Allan et al., 2005). They are produced
as large precursor protein by many cellular types on peripheral
and central immune system, such as blood monocytes and tissue
macrophages (Schumann et al., 1998; Denes et al., 2012). Pro-IL-
1β (31- to 33-kDa) is biologically inactive and then proteolytically
processed by caspase-1 resulting in a functional secretory 17-kDa
protein (Rubartelli et al., 1990; Schumann et al., 1998).
There are multiple steps of regulation of IL-1β production and
activity, including transcription, translation, cleavage, and cel-
lular secretion (Allan et al., 2005). In macrophages for example,
IL-1β activation involves two distinct, sequential and intracellu-
lar signals to produce IL-1β transcription and translation (van de
Veerdonk et al., 2011). Soluble IL-1β as well as IL-1α induces cel-
lular response through its binding to transmembrane receptors:
IL-1R1 or IL-1R3. A third speciﬁc ligand, the IL-1 receptor antag-
onist (IL-1ra) binds the IL-1R1 with similar speciﬁcity and afﬁnity
but does not activate the receptor and trigger downstream signal-
ing (Weber et al., 2010). IL-1R1 is found ubiquitously and IL-1R3
presents preferential neural tissue expression (Qian et al., 2012).
This is followed by recruitment of an accessory protein (IL-1RAcP,
called co-receptor) and then this trimeric complex starts signaling
by assembling the adaptor proteinMyD88 to theToll-IL-1R1 (TIR)
domain. Recently, a novel isoform of co-receptor (IL-1RAcPb)
was described, expressed mainly in the CNS (Huang et al., 2011).
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An additional receptor, IL-1R2, binds IL-1 with high afﬁnity but
does not transduce IL-1 signaling since it lacks an intracellular
domain (Dinarello,2011). Several kinases participate in the canon-
ical cascade including members of IL-1 receptor-activated protein
kinase (IRAK) family (Gosu et al., 2012) that ends in the nuclear
translocation of the transcription factor NF-κB (nuclear factor-
kappaB). Other signaling pathways activated by IL-1β involve
mitogen-activated protein family (MAP) and Src kinases (Lu et al.,
2005; Huang et al., 2011). In the healthy brain, the levels of IL-1β
are very low but its levels are increased after several conditions,
including damage and peripheral inﬂammation (Pitossi et al.,
1997; Laye et al., 2000). Induced central IL-1β is mainly produced
by microglia (Herx et al., 2000) but also by neurons (Silverman
et al., 2005). In the rat brain IL-1R1 mRNA is mainly localized in
neurons, in the hypothalamus and hippocampus (Turnbull and
Rivier, 1999).
Neurons have been shown to be particularly susceptible to
IL-1β-mediated toxicity. For example, Purkinje neurons suf-
fer apoptosis when microglia releases IL-1β and TNF-α (Kaur
et al., 2012). IL-1β primes neurons to undergo excitotoxic death.
IL-1β recruits various members of the MAP kinase pathway
that are known to control neurodegeneration mediated by over-
stimulation of the glutamate receptor (Doble, 1999). For example,
it has been demonstrated that during an acute attack of Multi-
ple Sclerosis (MS), inﬂammation increases brain IL-1β signaling,
which enhances in turn glutamate-mediated synaptic excitability
(Rossi et al., 2012).
FUNCTIONAL ROLE OF IL-1β IN PARKINSON’S DISEASE
IL-1β is a pro-inﬂammatory cytokine with pleiotropic biological
actions in the periphery and the brain. IL-1β has been found in
the cerebrospinal ﬂuid and post-mortem striata of PD patients
(Mogi et al., 1994, 1996; Nagatsu et al., 2000). In addition, IL-1β
gene polymorphisms have been associated with age-at-onset of
sporadic PD (Nishimura et al., 2000; McGeer et al., 2002; Wahner
et al., 2007), although not all reports lead to similar conclusions
(Nishimura et al., 2000; Liu et al., 2010; Pascale et al., 2011; Chu
et al., 2012).
As stated above, the ﬁnal functional outcome of IL-1β on
dopaminergic cell loss will depend on variables such as concen-
tration, duration of expression, and timing among stimuli. In
terms of the inﬂuence of the duration and levels of IL-1β expres-
sion, it is irrefutable that the sustained expression of IL-1β in
the SN at pro-inﬂammatory levels causes irreversible and pro-
nounced dopaminergic neuronal loss in the SN (Ferrari et al.,
2006; Pott Godoy et al., 2010). This conclusion is supported by
experiments performed in two different animal models. In one,
IL-1β expression in the SN was achieved via adenoviral vector
inoculation in that region (Ferrari et al., 2006). On the other
hand, the property of adenoviral vectors to retrogradely deliver
transgenes from the axonal terminals to the cell bodies was used
(Pott Godoy et al., 2010). In both models, IL-1β-mediated neu-
rodegeneration and motor symptoms were detected 21 days after
adenoviral administration although IL-1β expressionwas detected
much earlier (7 days). Therefore, sustained IL-1β expression was
required for delayed neurodegeneration and motor symptoms to
occur. Highlighting the relevance of a sustained in contrast to
the acute expression of IL-1β, the acute injection of IL-1β in the
SN was not toxic for dopaminergic neurons if the cytokine was
injected alone (10 ng or 1000 U) or in combination with 1000 U
of TNF-α and 100 U of interferon-gamma (IFN-γ; Castaño et al.,
2002; Depino et al., 2003). A slightly different result was reported
by other group where the acute injection of a similar dose of IL-1β
in the medial forebrain bundle produced a 12.2% decrease in the
cell counts in the SN 14 days post administration, but this decrease
was not statistically different from the cell counts of control ani-
mals (Carvey et al., 2005a). Moreover, IL-1β induced by the acute
administration of lipopolysaccharide (LPS) in the SNwas not toxic
(Koprich et al., 2008; Pott Godoy et al., 2008). Over all, the avail-
able data suggest that sustained but not acute IL-1β expression at
pro-inﬂammatory levels, has univocal toxic effects in the SN.
Concerning the state inwhich a dopaminergic neuron perceives
IL-1β signaling, it is important to notice that during neuronal
cell loss in PD, and also in prion and AD models, the surround-
ing microglial cells are activated to a particular state deﬁned as
“primed” or “atypical” (Perry et al., 2002; Depino et al., 2003;
Cunningham et al., 2005; Pott Godoy et al., 2008). In this state
of activation, microglial cells change their morphology, possess
phagocytic capacity but their array of secreted molecules do not
provoke a pro-inﬂammatory environment, as previously assumed.
In particular in PD, IL-1βmRNA levels are increased in the degen-
erating SN after 6-OHDA administration in the striatum but this
increment is not reﬂected at the protein level (Depino et al., 2003).
In other words, the activation of microglial cells during 6-OHDA-
mediated neurodegeneration augments IL-1β transcription but
not translation, inhibiting the assumed pro-inﬂammatory effect
of IL-1β production at the protein level. However, the transcrip-
tional block of IL-1βprotein expressionduringneurodegeneration
can be released by the administration of a sub-toxic dose of an
inﬂammogen such as LPS in the degenerating SN at the time when
microglial cells are already“primed”(Pott Godoy et al., 2008). This
treatment caused increased IL-1β production, which in turn exac-
erbated neurodegeneration in the SN and produced earlier and
increased motor symptoms in the treated animals (Pott Godoy
et al., 2008). The blockade of IL-1β biological activity inhibits the
observed exacerbation, implicating this cytokine as a main media-
tor of the observed effects. In conclusion, a central sub-toxic dose
of LPS that does not produce neuronal cell death per se in the SN
can exacerbate on-going neurodegeneration via IL-1β production
from primed microglial cells.
Importantly, in clinical terms, nigral neurodegeneration
elicited by two different treatments can be exacerbated from the
periphery by eliciting a sustained, succeeding intravenous inﬂam-
matory stimulus (Pott Godoy et al., 2008, 2010). Interestingly, in
both animal models tested, no neuronal death was observed if the
systemic inﬂammation was elicited in control animals suffering no
previous neurodegeneration (Pott Godoy et al., 2008, 2010).
In turn, Koprich et al. (2008), studied the effects of a pro-
inﬂammatory stimulus before instead of after 6-OHDA admin-
istration. They have shown that one stimulus of LPS in the SN
capable of inducing IL-1 production is not sufﬁcient to produce
tyrosine hydroxylase (TH) neuronal loss per se, but in the pres-
ence of a second challenge with 6-OHDA in the striatum, the
death of TH neurons was higher in the animals which received the
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pro-inﬂammatory and neurodegenerative stimuli (Koprich et al.,
2008). On the other hand, demonstrating the importance of con-
centration, timing, and nature of the inﬂammatory insult studied,
Saura et al. (2003) have shown that an acute infusion of a high
dose of recombinant IL-1β (20 ng) in the SN of rats 5 days prior to
the injection of 6-OHDA in the striatal region, protects dopamin-
ergic cellular bodies from 6-OHDA inducing a marked astroglial
but no microglia activation and preventing motor dysfunctions.
Therefore, even though most of the available evidence suggests
that an inﬂammatory stimulus previous to a neurodegenerative
treatment exacerbates neuronal cell death, protective effects under
speciﬁc circumstances cannot be ruled out.
Several lines of evidence suggest that astrocytes upregulate the
expression of inﬂammatory cytokines such as IL-1α, IL-1β, and
IL-6 and the release of TNF-α and IL-6 under pathological con-
ditions (Lee et al., 2010; Rappold and Tieu, 2010). In addition to
directly release pro-inﬂammatory cytokines, astrocytes can also be
activated by cytokines such as TNF-α and IL-1β from microglia,
leading to production of reactive oxygen and nitrogen species. For
example, a recent study demonstrated in a co-culture model, that
astrocytes enhance microglial inﬂammatory responses through
an NF-κB-dependent mechanism, leading to more dopaminer-
gic toxicity (Saijo et al., 2009); for a more in-depth review on the
functional role of astrocytes in PD, please refer to Rappold and
Tieu (2010).
TNF-α: GENERALITIES
The existence of an anti-tumoral response of the immune sys-
tem has been described about 100 years ago (Tsung and Norton,
2006). In 1968, TNF-α was identiﬁed as a soluble cytokine able
to exert signiﬁcant cytotoxicity on many tumor cell lines and to
cause tumor necrosis in certain animal model systems (Kolb and
Granger, 1968). The cDNA of TNF-αwas cloned and several years
later, two membrane receptors were identiﬁed (Old, 1985). TNF-
α is the prototypic member of a large cytokine family, the TNF
ligand family. TNF-α is primarily produced as a type II trans-
membrane protein arranged in stable homotrimers. From this
membrane-integrated form the soluble homotrimeric cytokine
[(soluble TNF-α (sTNF-α)] is released via proteolytic cleavage
by the metalloprotease TNF-α converting enzyme (TACE). The
soluble 51-kDa trimerics TNF tends to dissociate at concentra-
tions below the nanomolar range, thereby losing its bioactivity.
The members of the TNF-α ligand family exert their biological
functions via interaction with their cognate membrane receptors,
comprising the TNF receptor (TNFR) family (McCoy and Tansey,
2008).
Two receptors, TNFR1 (TNF receptor type 1; CD120a; p55/60)
and TNFR2 (TNF receptor type 2; CD120b; p75/80) bind
membrane-integrated TNF (memTNF) as well as sTNF (Banner
et al., 1993; McCoy and Tansey, 2008). TNFR1 is constitutively
expressed in most tissues, whereas expression of TNFR2 is highly
regulated and is typically found in cells of the immune system.
Generally, the importance of TNFR2 is likely to be underestimated,
because this receptor can only be fully activated by memTNF, but
not sTNF (McCoy and Tansey, 2008; Naude et al., 2011). The
cause for this difference is not fully understood yet, but the differ-
ent stabilities, that is half-lives, of the individual ligand/receptor
complexes may contribute to this (Naude et al., 2011). The extra-
cellular domains of both receptors can be proteolytically cleaved,
yielding soluble receptor fragments with higher potential neu-
tralizing capacity compared to their membrane-integrated forms
(Wallach et al., 1991). TNF-α neutralizing agents for clinical use
that were constructed on the basis of the soluble receptors have
therefore been engineered as dimeric immunoglobulin G (IgG)
fusionproteins. LikeTNF,TNFR2 is cleavedbyTACE.Theprocess-
ing enzyme(s) responsible for TNFR1 cleavage is still undeﬁned,
but TNFR1 cleavage is obviously an important step in the reg-
ulation of cellular TNF-α responsiveness, as cleavage-resistant
TNFR1 mutations are linked with dominantly inherited autoin-
ﬂammatory syndromes (TNFR1-associated periodic syndromes,
TRAPS). The intracellular domains of TNFR1 and TNFR2 that do
not possess any enzymatic activity deﬁne them as representatives
of the two main subgroups of the TNFR family, the death domain
(DD)-containing receptors and the TNF receptor-associated fac-
tor (TRAF)-interacting receptors, respectively. TNFR1 contains
a protein–protein interaction domain, called DD. The DD can
recruit otherDD-containing proteins and couples the death recep-
tors to caspase activation and apoptosis. In addition, TNFR1 is
also a potent activator of gene expression via indirect recruitment
of members of the TRAF family, TRAF2, 5, and 6 (Yoon et al.,
2008). TNFR2 directly recruits TRAF2, induces gene expression
and intensively crosstalk with TNFR1. Identically as IL-1β signal-
ing pathway, members of the TRAF family activate nuclear factor
NF-κB which induces gene expression (Wong et al., 1998). Activa-
tion of IL-1β, IL-6, and TNF-α pathways seems to have a negative
regulation loop by microRNA miR-146, which has IRAK1 and
TRAF6 as targets (Taganov et al., 2006) reviewed in Boldin and
Baltimore (2012).
Of interest, TNFRs can have counteracting functions, at least
in neuronal tissues, as recently demonstrated in a murine model
of retinal ischemia, where TNFR1 apparently aggravated tissue
destruction, whereas TNFR2 was protective via activation of
PKB/Akt. It has been proposed that TNFR1 or 2 speciﬁc ago-
nists and antagonists could mediate speciﬁc protective effects
in PD (McCoy and Tansey, 2008). In other words, it was pro-
posed that memTNF which is crucial in maintaining a normal
innate immune response to infections (Fremond et al., 2005; Saun-
ders et al., 2005; Torres et al., 2005; Alexopoulou et al., 2006;
Zalevsky et al., 2007; Allenbach et al., 2008; Naude et al., 2011)
should remain active, while sTNF should be pharmacologically
inhibited.
FUNCTIONAL ROLE OF TNF-α IN PARKINSON’S DISEASE
During chronic or acute neuroinﬂammation high levels of sTNF
are found in the cerebrospinal ﬂuid and post-mortembrains of PD
patients as well as in animals treated with dopaminergic neuro-
toxins as MPTP and 6-OHDA used to model nigral degeneration
in non-human primates and rodents (Boka et al., 1994; Hunot
et al., 1999; Mogi et al., 2000; Sriram et al., 2002; Barcia et al.,
2005; Nagatsu and Sawada, 2005). High expression of TNF at the
site where neurological damage occurs, suggests that this potent
pro-inﬂammatory cytokine is a mediator of neuronal injury,
and therefore, in principle, a feasible target for the treatment
of PD.
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Many genetically engineered mouse models were designed in
order to elucidate the contribution of TNF-α in neurodegenera-
tion. It should be noticed that this models have limitations and
they may not exactly reﬂect what happens in the brain of PD
patients. Despite of these restrictions these models had proven to
be very useful unraveling the role of TNF-α in this disease.
The effects of TNF-α on the nigrostriatal pathway were investi-
gated by administration of MPTP in knock-out mice lacking TNF-
α, or TNFRs. First reports showed that TNF-α was upregulated in
the striatum after MPTP administration (Sriram et al., 2002; Fer-
ger et al., 2004). Null mice for the TNF-α gene showed diminished
dopamine content loss in the striatum after MPTP administra-
tion but no differences in TH-positive cells in the SN, suggesting
an overall detrimental effect of TNF-α on dopamine metabolism
(Ferger et al., 2004). However, the same group reported that nei-
ther TNFR1 nor TNFR2 gene ablation showed protection against
MPTP chronic neurotoxicity, suggesting a TNFR-independent
mechanism (Leng et al., 2005). Additional work showed that dou-
ble knock-out mice for both TNFR were protected against the
effect of MPTP (Sriram et al., 2002). On the contrary, Rousse-
let et al., 2002 did not ﬁnd differences in the number of nigral
dopaminergic neurons between the wild type mice and the same
double TNFR knock-out mice after MPTP administration. In this
last work, the striatal dopamine level was even slightly decreased
in the knock-out mice, indicating a potential beneﬁcial effect
of TNF-α.
These conﬂicting results can be attributed to several method-
ological issues. The doses of MPTP used in these studies were
different [15 mg/kg on 8 consecutive days in Leng et al. (2005),
12.5 mg/kg in Sriram et al. (2002), and 60 mg/kg in Rousselet et al.
(2002)]. Also, Leng et al. (2005) performed their analysis at day 15
(7 days after the last injection) while Sriram et al. (2002) focused
their analysis between 24 and 48 h after MPTP injection and Rous-
selet et al. (2002) did it at day 10 p.i. These issues can account for
the dissimilar results since different regimes of administration of
MPTP lead to dramatic changes in the mechanism of cell death
(Furuya et al., 2004). Despite this fact, it is still unclear whether
TNF-α possess neurotoxic properties and by which TNFR may
exert its action in the MPTP model.
Similar contradictory results have been reported in rats injected
with the neurotoxin 6-OHDA in the striatum. McCoy et al. (2006)
reported that the toxic effects of 6-OHDA could be ameliorated by
a synthetic dominant negative TNF-α inhibitor called XENP345
only when infused in the SN, but had no effects in the striatum
(McCoy et al., 2006). Furthermore, inhibition of sTNF by injec-
tion of a lentiviral vector encoding a dominant negative TNF-α
in the SN of rats prevented further loss of nigral DA neurons
(McCoy et al., 2006; Harms et al., 2011). On the contrary, Gemma
et al. (2007) found that early inhibition of TNF-α by an antisense
oligodeoxyribonucleotide (days 1–7 after 6-OHDA insult) could
be neurotoxic, but late inhibition (days 7–15) was neuroprotective
(Gemma et al., 2007). These ﬁnding could indicate a dual role of
TNF-α, being neuroprotective during the early steps of injury and
neurotoxic when chronically induced.
In vitro, TNF-α administration or expression has been shown
to be toxic to dopaminergic neurons (McGuire et al., 2001; Gayle
et al., 2002; Sriram et al., 2002, 2006). In vivo, many reports show
detrimental effects of TNF-α injection or overexpression in the
SN, but contrary results have also been reported.
Following acute TNF-α administration (1000U or 20 ng) in the
SN, Castaño et al. (2002) could not detect a degenerative effect.
In line with this observation, the overexpression of TNF-α via
adenoviral vectors in the SN (eliciting an average of 500 pg of
TNF-α) did not evoke a toxic effect on dopaminergic neurons
up to 7 days after beginning of its expression (De Lella Ezcurra
et al., 2010). However, in one report the acute administration of a
100- to 400-fold higher dose of TNF-α than in the previous study
triggered dopaminergic cell loss in the SN at 14 but not 7 days
post-inoculation (Carvey et al., 2005b). Therefore, in conclusion,
most of the available evidence suggests that acute TNF expression
at pathophysiological levels is not overtly toxic in the SN.
In experiments where TNF-α was expressed chronically, toxic
effects of TNF-α were clearly observed. An early report by Aloe
and Fiore (1997) showed that TNF-α overexpression in the CNS
of transgenic mice lead to reduced TH immunoreactivity in the
striatum. The effects of chronic, upregulated low levels of TNF-
α were investigated by De Lella Ezcurra et al. (2010). Intranigral
injection of an adenoviral vector encoding soluble mouse TNF-α
providing chronic expression of this cytokine in rats showed a pro-
gressive neurodegenerative effect which causes forelimb akinesia
and a distinct inﬂammatory response in the rat brain (De Lella
Ezcurra et al., 2010). These effects were observed from day 14 post
adenoviral inoculation. In addition, Chertoff et al. (2011) studied
the effect of TNF-α in the SN of adult mice inducing the chronic
expression of this cytokine using a combination of hypomorphic
mice where TNF-α expression was controlled by the endogenous
engrailed promoter, adenoviral vectors, and the CRE/loxP sys-
tem. In line with the ﬁnding discussed before, chronic upregulated
expression of TNF resulted in a progressive loss of DA neurons in
the SN and their terminals and monocyte/macrophage recruit-
ment (Chertoff et al., 2011). All together these results indicate
that long term expression of pro-inﬂammatory levels of TNF-α
[or acute but very high expression,as reported by Carvey et al.
(2005b)] seems to be necessary to exert univocal and toxic effects
in the SN.
However, if lower levels of TNF-α were expressed in the SN,
a transient neuroprotective effect against 6-OHDA toxicity in the
SN and in the striatum was observed (Chertoff et al., 2011). In
developmental studies, if the TNF-α expressionwas elicited during
the second week of pregnancy by LPS injection, a toxic effect on
adult dopaminergic neurons was detected in the adult naïve or 6-
OHDA challenged SN (Ling et al., 2002, 2004; Carvey et al., 2003).
The cholinergic anti-inﬂammatory pathway should also be
taken into account in order to understand the contribution of
TNF-α in PD. This pathway regulates the innate immune response
after injury or infection. After an insult, TNF-α (and other
cytokines) are produced by the cells of the innate immune system,
augmenting andprolonging the inﬂammatory response by activat-
ing other cells to release many cytokines (i.e., IL-1β). This initial
beneﬁcial response can be detrimental if it lasts for a long time or it
is exacerbated. As a way to control this response, TNF-α stimulates
the afferent branch of the vagus nerve which conveys this signal
to the CNS. In turn, the motor branch of the vagus nerve releases
acetylcholine in the periphery. In particular, this neurotransmitter
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interacts with the alpha7 subunit of the nicotinic acetylcholine
receptor expressed in macrophages, and other cytokine-releasing
cells. This interaction activates intracellular signal transduction
which inhibits release of pro-inﬂammatory cytokines, in particular
TNF-α. This negative feedback circuit regulates the inﬂamma-
tory response, maintaining homeostasis (Tracey, 2002), reviewed
in Tracey et al. (2008). A similar cholinergic pathway exists in
the brain, regulating microglial activation (Shytle et al., 2004).
In addition, IL-1β promotes the synthesis of acetylcholinesterase
(Li et al., 2000), which would decrease acetylcholine and promote
inﬂammation.
These ﬁndings may have therapeutic consequences. Vagal
stimulation has proven effective for the treatment of epileptic
seizures refractory to pharmacological treatments in adult patients
(Ben-Menachem et al., 1994; Groves and Brown, 2005; Tecoma
and Iragui, 2006) and possible applications for PD patients are
foreseen (Bokkala-Pinninti et al., 2008). Speciﬁcally in PD, an
inverse correlation has been found between nicotine (a ligand
for the alpha7 nicotinic receptor) consumption and the risk of
PD development. Regarding this, Park et al. (2007) reported that
micromolar concentration of this compound signiﬁcantly reduced
release of TNF-α and loss of DA neurons in vitro, in a LPS
model.
INTERACTIONS BETWEEN IL-1β AND TNF-α
The neuroimmunology of the brain parenchyma differs in many
aspects from the immune response elicit systemically (for extensive
review see Lowenstein and Castro, 2003; Perry et al., 2010; Roca
et al., 2011). In relation with the interaction between IL-1β and
TNF-α, the cytokine network in the brain parenchymadiffers from
the periphery. Whereas in the periphery IL-1β production leads
to TNF production (and vice versa) in an overwhelming majority
of models and experimental conditions (Luger and Schwarz, 1990;
Creasey et al., 1991; Chuluyan et al., 1998), the mutual induction
of one cytokine by the other is restricted in the CNS. It has been
demonstrated that the injection in the brain parenchyma of IL-1β
triggers IL-1βmRNA and protein synthesis but not TNF-α expres-
sion (Blond et al., 2002; Depino et al., 2005). In addition, TNF-α
injection in the brain parenchyma does not induce TNF-α itself or
any IL-1β beta expression (Blond et al., 2002). These observations
hold true even if IL-1β or TNF-α are expressed chronically in the
SN or the striatum using adenoviral vectors (Ferrari et al., 2004,
2006; De Lella Ezcurra et al., 2010).
In parallel and in accordance to a restricted presence of one
cytokine and not the other in the brain parenchyma, the pattern
of leukocyte recruitment to the brain triggered by each of these two
primordial pro-inﬂammatory cytokines is different. IL-1β seems
to recruit preferentially neutrophils and polymorphonuclear cells;
while TNF-α calls formononuclear cell inﬁltration (Anthony et al.,
1997; Schnell et al., 1999; Blond et al., 2002; Ferrari et al., 2004,
2006; Depino et al., 2005; De Lella Ezcurra et al., 2010).
Therefore, under the light of the restricted induction of each
other, the evidence described here on their functional role in
PD could be mainly associated to one cytokine and not to the
other.
Given the fact that around 30% of PD patients may develop
symptoms related to AD, it is relevant to note that the current
evidence points also compellingly toward a central role for
inﬂammation in AD. The observed neuroinﬂammation would
create a chronic and self-sustaining interaction between acti-
vated microglia and astrocytes, stressed neurons, and Aβ plaques
(Rubio-Perez and Morillas-Ruiz, 2012). In addition, a clinical
study involving 300 patients correlates cognitive decline with the
occurrence of systemic inﬂammation in AD patients (Holmes
et al., 2003). Overexpression of mutant forms of amyloid β-
protein precursor (APP) in the brains of transgenicmice produced
amyloid plaques surrounded by activated microglia and reactive
astrocytes and upregulated IL-1β, IL-6, and TNF-α, which resem-
bled the alterations found in patientswithAD (Morgan et al., 2005;
Jin et al., 2008). In this sense, therapies using an anti-TNF-α fusion
protein produced sustained clinical improvement in a 6-month,
open-label pilot study in patients with AD ranging from mild to
severe (Tobinick, 2009).
CONCLUSION
In conclusion, as expected for molecules with pleiotropic func-
tions, the net, univocal effects of IL-1β or TNF-α on dopaminergic
neuronal viability in vivo depends on a number of variables.
Although cytokine biology is not prone to generalizations, in this
case the available evidence tempts us to suggest that, in the healthy
SN, these variables can be mainly circumscribed to duration and
levels of expression (see Figure 1A). As stated above, IL-1β and
TNF-α effects in the brain could be distinctly separated from
each other, since they are not mutually inducible in the brain
parenchyma. However, the inﬂuence of these variables on their
net functional effect seems to be similar in general terms. In the
healthy SN (Figure 1A), the acute administration or expression of
both cytokines seems to have no dramatic effect on dopaminergic
neurons in the SN, unless expressed at supra-physiological levels
(Castaño et al., 2002; Depino et al., 2003; Saura et al., 2003; Carvey
et al., 2005a; Koprich et al., 2008). On the contrary, sustained
FIGURE 1 | Schematic representation of a working framework to study
the functional effects of IL-1β andTNF-α on dopaminergic neurons in
vivo according to duration and levels of expression in the healthy SN
(A) or in the degenerating SN (B). Clear effects are only seen at the
extremes of the scheme or when a pro-inﬂammatory stimulus hits the
already degenerating SN.
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levels of IL-1β or TNF-α have been associated with neurodegen-
eration in the SN (Aloe and Fiore, 1997; Ferrari et al., 2006; De
Lella Ezcurra et al., 2010; Pott Godoy et al., 2010; Chertoff et al.,
2011).In terms of dosage, low levels of these cytokines have pro-
duced either no or neuroprotective effects (Depino et al., 2003;
Chertoff et al., 2011) whereas high, pro-inﬂammatory levels pro-
duced univocally neuronal demise in the naïve SN (Ferrari et al.,
2006; Pott Godoy et al., 2010; Chertoff et al., 2011). The over-
whelming evidence accumulated suggests that the combination of
both variables increased the prediction of the net biological effect
of IL-1β or TNF-α on the SN (Figure 1A). In other words, sus-
tained and high IL-1β and TNF-α expression will univocally lead
to neurodegeneration, while acute and low expression will lead to
no or neuroprotective effects.
It is also clear that, in the degenerating SN, when microglial
cells are primed, acute and sub-toxic pro-inﬂammatory stimuli
irreversibly leads to increased neurodegeneration (Figure 1B; Pott
Godoy et al., 2008, 2010). If IL-1β is expressed before neurode-
generation, it can increase susceptibility to 6-OHDA (Koprich
et al., 2008) or have neuroprotective effects (Saura et al., 2003)
depending on other variables. In the case of TNF-α, the only
report studying the effects of low TNF-α levels in the adult SN
before 6-OHDA administration shows a neuroprotective effect
(Chertoff et al., 2011). However, several developmental studies
have shown a toxic effect on adult dopaminergic neurons of
LPS-derived TNF-α when administered during the second ges-
tation week in the rat (Ling et al., 2002, 2004; Carvey et al., 2003).
Therefore, when the SN is subjected to IL-1β or TNF-α before
a neurodegenerative stimulus, the ﬁnal effect depends on other
variables.
Hence, if these variables are affecting IL-1β and TNF-α effects
on dopaminergic viability, how can this information be trans-
lated to future treatments to PD patients where these variables are
uncontrollable and not measurable?
Indeed, a similar scenario has occurred in theMSﬁeld. MS is an
autoimmune demyelinating disease whose inﬂammatory compo-
nent ismuchmore characterized and typical than in PD. Inmodels
of MS, TNF-α accelerated the onset of disease and increased
apoptosis of oligodendrocytes (Caminero et al., 2011). Based on
numerous and sound studies in vitro and in vivo demonstrating
toxic effects of TNF-α, clinical trials using anti-TNF-α molecules
were approved and started (Caminero et al., 2011). Unfortunately,
anti-TNF-α therapies failed to improve, or even worsened, the
symptoms of MS patients treated (Caminero et al., 2011). Later
it was found that TNF-α can have also beneﬁcial effects on MS
progression such as promoting the regression of myelin-speciﬁc
T cell activity at later time points (Kassiotis et al., 2001) and
inducing the proliferation of oligodendrocyte progenitors (Arnett
et al., 2001). Also, TNFR1 seems to mediate demyelination while
TNFR2 preferentially induces remyelination, calling for TNFR-
speciﬁc therapies (Caminero et al., 2011). Therefore, it can be
suggested that the disappointing results of the anti-TNF-α clinical
trials against MS were due to the inhibition of previously unrecog-
nized beneﬁcial effects of this cytokine and/or unspeciﬁc receptor
activation.
Thus, how can we learn from the MS ﬁeld and design clinical
trials with a higher probability of achieving therapeutic efﬁcacy?
Based on the evidence discuss in this review, we are certain
that general anti-IL-1β or TNF-α therapies against PD have low
probability of success. In a similar way, general anti-inﬂammatory
treatments may inhibit toxic but also beneﬁcial effects of TNF-α,
IL-1β, or other cytokines.
One possibility to increase the success rate of future clinical
trials could be to use receptor-speciﬁc agonists or antagonists to
circumvent undesired effects of general anti-inﬂammatory or spe-
ciﬁc anti-IL-1β or TNF-α therapies against PD. This option has
been suggested especially for TNF-α, where the different biolog-
ical effects of TNFR1 and TNFR2 have been more exhaustively
studied (McCoy and Tansey, 2008). In addition, taking advantage
of the biological differences of memTNF and sTNF on their recep-
tor binding, several speciﬁc inhibitors have been designed on these
bases (Moreland, 1998; Deswal et al., 1999; Zalevsky et al., 2007;
Gonzales et al., 2008; Mukai et al., 2009).
Finally, we believe that there are common and speciﬁc down-
stream mediators of the toxic effects of IL-1β and TNF on
dopaminergic neurons in the SN.The identiﬁcationof these IL-1β-
or TNF-derived molecules with univocal toxic effects should open
the possibility to inhibit IL-1β or TNF-α-detrimental effects while
sparing their neuroprotective properties, increasing the probabil-
ity of efﬁcacy in a clinical setting. A similar, but reverse rational
can be applied to neuroprotective-only molecules. Fortunately,
numerous animalmodels and experimental set-ups have been gen-
erated in the past 10 years to be able to identify these candidate
molecules.
Undoubtedly, neuroinﬂammation is no longer regarded as the
expected consequence of neuronal demise leading to the clear-
ance of cell debris, but a phenomenon dramatically affecting PD
progression and therefore a target for neuroprotective or disease-
modifying therapies. The actual challenge is to reach the clinic
with compounds univocally targeting the detrimental effects of
neuroinﬂammation, sparing possible beneﬁcial effects of these
pleiotropic molecules.
REFERENCES
Alexopoulou, L., Kranidioti, K., Xan-
thoulea, S., Denis, M., Kotanidou, A.,
Douni, E., et al. (2006). Transmem-
brane TNF protects mutant mice
against intracellular bacterial infec-
tions, chronic inﬂammation and
autoimmunity. Eur. J. Immunol. 36,
2768–2780.
Aloe, L., and Fiore, M. (1997).
TNF-alpha expressed in the brain
of transgenic mice lowers central
tyroxine hydroxylase immunoreac-
tivity and alters grooming behavior.
Neurosci. Lett. 238, 65–68.
Allan, S. M., Tyrrell, P. J., and Rothwell,
N. J. (2005). Interleukin-1 and neu-
ronal injury. Nat. Rev. Immunol. 5,
629–640.
Allenbach, C., Launois, P., Mueller,
C., and Tacchini-Cottier, F. (2008).
An essential role for transmembrane
TNF in the resolution of the inﬂam-
matory lesion induced by Leishmania
major infection. Eur. J. Immunol. 38,
720–731.
Anthony, D. C., Bolton, S. J., Fearn,
S., and Perry, V. H. (1997). Age-
related effects of interleukin-1 beta
on polymorphonuclear neutrophil-
dependent increases in blood-brain
barrier permeability in rats. Brain
120, 435–444.
Arnett, H. A., Mason, J., Marino,
M., Suzuki, K., Matsushima, G.
K., and Ting, J. P. (2001). TNF
alpha promotes proliferation of
oligodendrocyte progenitors and
remyelination. Nat. Neurosci. 4,
1116–1122.
Banner, D. W., D’arcy, A., Janes,
W., Gentz, R., Schoenfeld, H. J.,
Broger, C., et al. (1993). Crystal
structure of the soluble human
55 kd TNF receptor-human TNF
beta complex: implications for
TNF receptor activation. Cell 73,
431–445.
Frontiers in Cellular Neuroscience www.frontiersin.org April 2013 | Volume 7 | Article 53 | 7
“fncel-07-00053” — 2013/4/25 — 22:14 — page 8 — #8
Leal et al. IL-1 andTNF in Parkinson’s Disease
Barcia, C., De Pablos, V., Bautista-
Hernandez, V., Sanchez-Bahillo, A.,
Bernal, I., Fernandez-Villalba, E.,
et al. (2005). Increased plasma lev-
els of TNF-alpha but not of IL1-
beta in MPTP-treated monkeys one
year after the MPTP administration.
Parkinsonism Relat. Disord. 11,
435–439.
Belin, A. C., Ran, C., Anvret, A., Pad-
dock, S., Westerlund, M., Håkans-
son, A., et al. (2012). Association of
a protective paraoxonase 1 (PON1)
polymorphism in Parkinson’s dis-
ease. Neurosci. Lett. 522, 30–35.
Ben-Menachem, E., Manon-Espaillat,
R., Ristanovic, R., Wilder, B. J., Ste-
fan,H.,Mirza,W., et al. (1994). Vagus
nerve stimulation for treatment of
partial seizures: 1. A controlled study
of effect on seizures. First Interna-
tionalVagus Nerve Stimulation Study
Group. Epilepsia 35, 616–626.
Benmoyal-Segal, L., Vander, T., Shif-
man, S., Bryk, B., Ebstein, R.
P., Marcus, E. L., et al. (2005).
Acetylcholinesterase/paraoxonase
interactions increase the risk of
insecticide-induced Parkinson’s
disease. FASEB J. 19, 452–454.
Bernheimer, H., Birkmayer, W.,
Hornykiewicz, O., Jellinger, K.,
and Seitelberger, F. (1973). Brain
dopamine and the syndromes of
Parkinson and Huntington. Clini-
cal, morphological and neurochem-
ical correlations. J. Neurol. Sci. 20,
415–455.
Blond, D., Campbell, S. J., Butchart,
A. G., Perry, V. H., and Anthony, D.
C. (2002). Differential induction of
interleukin-1beta and tumour necro-
sis factor-alpha may account for spe-
ciﬁc patterns of leukocyte recruit-
ment in the brain. Brain Res. 958,
89–99.
Boka, G., Anglade, P., Wallach, D.,
Javoy-Agid, F., Agid, Y., and Hirsch,
E. C. (1994). Immunocytochemical
analysis of tumor necrosis factor and
its receptors in Parkinson’s disease.
Neurosci. Lett. 172, 151–154.
Bokkala-Pinninti, S., Pinninti, N., and
Jenssen, S. (2008). Vagus nerve
stimulation effective for focal motor
seizures and focal interictal parkin-
sonian symptoms. A case report. J.
Neurol. 255, 301–302.
Boldin, M. P., and Baltimore, D. (2012).
MicroRNAs, new effectors and regu-
lators of NF-kappaB. Immunol. Rev.
246, 205–220.
Caminero, A., Comabella, M., and
Montalban, X. (2011). Tumor necro-
sis factor alpha (TNF-alpha), anti-
TNF-alpha and demyelination revis-
ited: an ongoing story. J. Neuroim-
munol. 234, 1–6.
Carvey, P. M., Chang, Q., Lipton, J. W.,
and Ling, Z. (2003). Prenatal expo-
sure to the bacteriotoxin lipopolysac-
charide leads to long-term losses of
dopamine neurons in offspring: a
potential, new model of Parkinson’s
disease. Front. Biosci. 8, s826–s837.
Carvey, P. M., Chen, E. Y., Lipton, J. W.,
Tong, C. W., Chang, Q. A., and
Ling, Z. D. (2005a). Intra-
parenchymal injection of tumor
necrosis factor-alpha and interleukin
1-beta produces dopamine neuron
loss in the rat. J. Neural Transm. 112,
601–612.
Carvey, P. M., Zhao, C. H., Hendey, B.,
Lum,H., Trachtenberg, J.,Desai, B. S.,
et al. (2005b). 6-Hydroxydopamine-
induced alterations in blood–brain
barrier permeability. Eur. J. Neurosci.
22, 1158–1168.
Castaño, A., Herrera, A., Cano, J., and
Machado, A. (2002). The degener-
ative effect of a single intranigral
injection of LPS on the dopaminergic
system is prevented by dexametha-
sone, and not mimicked by rh-TNF-
α, IL-1β and IFN-δ. J. Neurochem. 81,
150–157.
Chen, H., Jacobs, E., Schwarzschild,
M. A., Mccullough, M. L., Calle, E.
E., Thun, M. J., et al. (2005). Non-
steroidal antiinﬂammatory drug use
and the risk for Parkinson’s disease.
Ann. Neurol. 58, 963–967.
Chen, H., O’reilly, E. J., Schwarzschild,
M. A., and Ascherio, A. (2008).
Peripheral inﬂammatory biomarkers
and risk of Parkinson’s disease. Am. J.
Epidemiol. 167, 90–95.
Chertoff,M.,Di Paolo,N., Schoeneberg,
A., Depino, A., Ferrari, C., Wurst,
W., et al. (2011). Neuroprotective
and neurodegenerative effects of the
chronic expression of tumor necro-
sis factor alpha in the nigrostriatal
dopaminergic circuit of adult mice.
Exp. Neurol. 227, 237–251.
Chu, K., Zhou, X., and Luo, B. Y. (2012).
Cytokine gene polymorphisms and
Parkinson’s disease: a meta-analysis.
Can. J. Neurol. Sci. 39, 58–64.
Chuluyan, H. E., Lang, B. J., Yoshimura,
T., Kenney, J. S., and Issekutz, A.
C. (1998). Chemokine production
and adhesion molecule expression by
neural cells exposed to IL-1, TNF
alpha and interferon gamma. Life Sci.
63, 1939–1952.
Coelho, M., and Ferreira, J. J. (2012).
Late-stage Parkinson disease. Nat.
Rev. Neurol. 8, 435–442.
Creasey, A. A., Stevens, P., Kenney, J.,
Allison, A. C., Warren, K., Catlett,
R., et al. (1991). Endotoxin and
cytokine proﬁle in plasma of baboons
challenged with lethal and sublethal
Escherichia coli. Circ. Shock 33, 84–91.
Cunningham, C., Wilcockson, D. C.,
Campion, S., Lunnon, K., and
Perry, V. H. (2005). Central and sys-
temic endotoxin challenges exacer-
bate the local inﬂammatory response
and increase neuronal death during
chronic neurodegeneration. J. Neu-
rosci. 25, 9275–9284.
De Lella Ezcurra, A. L., Chertoff, M.,
Ferrari, C., Graciarena, M., and
Pitossi, F. (2010). Chronic expres-
sion of low levels of tumor necrosis
factor-alpha in the substantia nigra
elicits progressive neurodegener-
ation, delayed motor symptoms
and microglia/macrophage acti-
vation. Neurobiol. Dis. 37,
630–640.
Denes, A., Lopez-Castejon, G., and
Brough, D. (2012). Caspase-1: is IL-1
just the tip of the ICEberg? Cell Death
Dis. 3, e338.
Depino, A., Earl, C., Kaczmarczyk, E.,
Ferrari, C., Besedovsky, H., Del Rey,
A., et al. (2003). Microglial activa-
tion with atypical pro-inﬂammatory
cytokine expression in a rat model of
Parkinson’s disease. Eur. J. Neurosci.
18, 2731–2742.
Depino, A., Ferrari, C., Pott Godoy,
M. C., Tarelli, R., and Pitossi,
F. J. (2005). Differential effects of
interleukin-1beta on neurotoxicity,
cytokine induction and glial reaction
in speciﬁc brain regions. J. Neuroim-
munol. 168, 96–110.
Deswal, A., Bozkurt, B., Seta, Y., Parilti-
Eiswirth, S., Hayes, F. A., Blosch,
C., et al. (1999). Safety and efﬁcacy
of a soluble P75 tumor necrosis fac-
tor receptor (Enbrel, etanercept) in
patients with advanced heart failure.
Circulation 99, 3224–3226.
Dinarello, C. A. (1996). Biologic basis
for interleukin-1 in disease. Blood 87,
2095–2147.
Dinarello, C. A. (2011). Interleukin-
1 in the pathogenesis and treatment
of inﬂammatory diseases. Blood 117,
3720–3732.
Doble, A. (1999). The role of excito-
toxicity in neurodegenerative disease:
implications for therapy. Pharmacol.
Ther. 81, 163–221.
Ferger, B., Leng, A., Mura, A., Hen-
gerer, B., and Feldon, J. (2004).
Genetic ablation of tumor necro-
sis factor-alpha (TNF-alpha) and
pharmacological inhibition of TNF-
synthesis attenuates MPTP toxicity in
mouse striatum. J. Neurochem. 89,
822–833.
Ferrari, C. C., Depino, A. M., Prada, F.,
Muraro, N., Campbell, S., Podhajcer,
O., et al. (2004). Reversible demyeli-
nation, blood–brain barrier break-
down, and pronounced neutrophil
recruitment induced by chronic IL-1
expression in the brain. Am. J. Pathol.
165, 1827–1837.
Ferrari, C. C., Pott Godoy,M. C., Tarelli,
R., Chertoff, M., Depino, A. M., and
Pitossi, F. J. (2006). Progressive neu-
rodegeneration and motor disabili-
ties induced by chronic expression
of IL-1beta in the substantia nigra.
Neurobiol. Dis. 24, 183–193.
Fremond, C., Allie, N., Dambuza,
I., Grivennikov, S. I., Yeremeev, V.,
Quesniaux, V. F., et al. (2005). Mem-
brane TNF confers protection to
acute mycobacterial infection. Respir.
Res. 6, 136.
Furuya, T., Hayakawa, H., Yamada, M.,
Yoshimi, K., Hisahara, S., Miura, M.,
et al. (2004). Caspase-11 mediates
inﬂammatory dopaminergic cell
death in the 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine mouse
model of Parkinson’s disease. J.
Neurosci. 24, 1865–1872.
Gayle, D. A., Ling, Z., Tong, C., Landers,
T., Lipton, J. W., and Carvey, P. M.
(2002). Lipopolysaccharide (LPS)-
induced dopamine cell loss in cul-
ture: roles of tumor necrosis factor-
alpha, interleukin-1beta, and nitric
oxide. Brain Res. Dev. Brain Res. 133,
27–35.
Gemma, C., Catlow, B., Cole, M., Hud-
son, C., Samec, A., Shah, N., et al.
(2007). Early inhibition of TNFal-
pha increases 6-hydroxydopamine-
induced striatal degeneration. Brain
Res. 1147, 240–247.
Gonzales, P. E., Galli, J. D., and
Milla, M. E. (2008). Identiﬁcation
of key sequence determinants for the
inhibitory function of the prodomain
of TACE. Biochemistry 47, 9911–
9919.
Gosu, V., Basith, S., Durai, P., and Choi,
S. (2012). Molecular evolution and
structural features of IRAK family
members. PLoS ONE 7:e49771. doi:
10.1371/journal.pone.0049771
Groves, D. A., and Brown, V. J. (2005).
Vagal nerve stimulation: a review
of its applications and potential
mechanisms that mediate its clinical
effects. Neurosci. Biobehav. Rev. 29,
493–500.
Harms, A. S., Barnum, C. J., Ruhn, K.
A., Varghese, S., Trevino, I., Blesch,
A., et al. (2011). Delayed dominant-
negative TNF gene therapy halts pro-
gressive loss of nigral dopaminergic
neurons in a rat model of Parkinson’s
disease. Mol. Ther. 19, 46–52.
Herx, L. M., Rivest, S., and Yong, V.
W. (2000). Central nervous system-
initiated inﬂammation and neu-
rotrophism in trauma: IL-1 beta is
required for the production of ciliary
neurotrophic factor. J. Immunol. 165,
2232–2239.
Frontiers in Cellular Neuroscience www.frontiersin.org April 2013 | Volume 7 | Article 53 | 8
“fncel-07-00053” — 2013/4/25 — 22:14 — page 9 — #9
Leal et al. IL-1 andTNF in Parkinson’s Disease
Holmes, C., El-Okl, M., Williams, A.
L., Cunningham, C., Wilcockson, D.,
and Perry, V. H. (2003). Systemic
infection, interleukin 1beta, and cog-
nitive decline in Alzheimer’s disease.
J. Neurol. Neurosurg. Psychiatr. 74,
788–789.
Huang, Y., Smith, D. E., Ibanez-
Sandoval, O., Sims, J. E., and Fried-
man, W. J. (2011). Neuron-speciﬁc
effects of interleukin-1beta are medi-
ated by a novel isoform of the IL-1
receptor accessory protein. J. Neu-
rosci. 31, 18048–18059.
Hunot, S., Dugas, N., Faucheux, B.,
Hartmann, A., Tardieu, M., Debre,
P., et al. (1999). FcepsilonRII/CD23
is expressed in Parkinson’s disease
and induces, in vitro, production
of nitric oxide and tumor necrosis
factor-alpha in glial cells. J. Neurosci.
19, 3440–3447.
Jin, J. J., Kim, H. D., Maxwell, J. A.,
Li, L., and Fukuchi, K. (2008). Toll-
like receptor 4-dependent upregu-
lation of cytokines in a transgenic
mouse model of Alzheimer’s disease.
J. Neuroinﬂammation 5, 23.
Kassiotis, G., Kranidioti, K., and Kol-
lias, G. (2001). Defective CD4T cell
priming and resistance to experimen-
tal autoimmune encephalomyelitis in
TNF-deﬁcient mice due to innate
immune hypo-responsiveness. J.
Neuroimmunol. 119, 239–247.
Kaur, C., Sivakumar, V., Zou, Z.,
and Ling, E. A. (2012). Microglia-
derived proinﬂammatory cytokines
tumor necrosis factor-alpha and
interleukin-1beta induce Purkinje
neuronal apoptosis via their receptors
in hypoxic neonatal rat brain. Brain
Struct. Funct. doi: 10.1007/s00429-
012-0491-5 [Epub ahead of print].
Kolb, W. P., and Granger, G. A. (1968).
Lymphocyte in vitro cytotoxicity:
characterization of human lympho-
toxin. Proc. Natl. Acad. Sci. U.S.A. 61,
1250–1255.
Koprich, J. B., Reske-Nielsen, C.,Mithal,
P., and Isacson, O. (2008). Neuroin-
ﬂammation mediated by IL-1beta
increases susceptibility of dopamine
neurons to degeneration in an ani-
mal model of Parkinson’s disease. J.
Neuroinﬂammation 5, 8.
Laye, S., Gheusi, G., Cremona, S.,
Combe, C., Kelley, K., Dantzer,
R., et al. (2000). Endogenous brain
IL-1 mediates LPS-induced anorexia
and hypothalamic cytokine expres-
sion. Am. J. Physiol. Regul. Integr.
Comp. Physiol. 279, R93–R98.
Lee, H. J., Kim, C., and Lee, S. J. (2010).
Alpha-synuclein stimulationof astro-
cytes: potential role for neuroinﬂam-
mation and neuroprotection. Oxid.
Med. Cell. Longev. 3, 283–287.
Leng, A., Mura, A., Feldon, J., and Fer-
ger, B. (2005). Tumor necrosis factor-
alpha receptor ablation in a chronic
MPTP mouse model of Parkin-
son’s disease. Neurosci. Lett. 375,
107–111.
Lesage, S., and Brice, A. (2009). Parkin-
son’s disease: from monogenic forms
to genetic susceptibility factors. Hum.
Mol. Genet. 18, R48–R59.
Li, Y., Liu, L., Kang, J., Sheng, J. G.,
Barger, S. W., Mrak, R. E., et al.
(2000). Neuronal–glial interactions
mediated by interleukin-1 enhance
neuronal acetylcholinesterase activity
and mRNA expression. J. Neurosci.
20, 149–155.
Ling, Z., Gayle, D. A., Ma, S. Y., Lip-
ton, J. W., Tong, C. W., Hong, J. S.,
et al. (2002). In utero bacterial endo-
toxin exposure causes loss of tyrosine
hydroxylase neurons in the postna-
tal rat midbrain. Mov. Disord. 17,
116–124.
Ling, Z. D., Chang, Q., Lipton,
J. W., Tong, C. W., Landers, T.
M., and Carvey, P. M. (2004).
Combined toxicity of prenatal bac-
terial endotoxin exposure and post-
natal 6-hydroxydopamine in the
adult rat midbrain. Neuroscience 124,
619–628.
Liu, G. J., Feng, R. N., Luo, C., and Bi, S.
(2010). Lack of association between
interleukin-1 alpha, beta polymor-
phisms and Parkinson’s disease. Neu-
rosci. Lett. 480, 158–161.
Lowenstein, P. R., and Castro, M. G.
(2003). Inﬂammation and adaptive
immune responses to adenoviral vec-
tors injected into the brain: peculiari-
ties, mechanisms, and consequences.
Gene Ther. 10, 946–954.
Lu, K. T., Wang, Y. W., Wo, Y.
Y., and Yang, Y. L. (2005).
Extracellular signal-regulated kinase-
mediated IL-1-induced cortical
neuron damage during traumatic
brain injury. Neurosci. Lett. 386,
40–45.
Luger, T. A., and Schwarz, T. (1990).
Evidence for an epidermal cytokine
network. J. Invest. Dermatol. 95,
100S–104S.
McCoy, M. K., Martinez, T. N., Ruhn,
K. A., Szymkowski, D. E., Smith, C.
G., Botterman, B. R., et al. (2006).
Blocking soluble tumor necrosis fac-
tor signaling with dominant-negative
tumor necrosis factor inhibitor atten-
uates loss of dopaminergic neurons
in models of Parkinson’s disease. J.
Neurosci. 26, 9365–9375.
McCoy,M.K., andTansey,M.G. (2008).
TNF signaling inhibition in the CNS:
implications for normal brain func-
tion and neurodegenerative disease.
J. Neuroinﬂammation 5, 45.
McGeer, P. L., Yasojima, K., and
McGeer, E. G. (2002). Associa-
tion of interleukin-1 beta poly-
morphisms with idiopathic Parkin-
son’s disease. Neurosci. Lett. 326,
67–69.
McGuire, S. O., Ling, Z. D., Lip-
ton, J. W., Sortwell, C. E., Col-
lier, T. J., and Carvey, P. M.
(2001). Tumor necrosis factor alpha
is toxic to embryonic mesencephalic
dopamine neurons. Exp. Neurol. 169,
219–230.
Mogi, M., Harada, M., Kondo, T.,
Riederer, P., Inagaki, H., Minami,
M., et al. (1994). Interleukin-1β,
interleukin-6, epidermal growth fac-
tor and transforming growth factor-α
are elevated in the brain from parkin-
sonian patients. Neurosci. Lett. 180,
147–150.
Mogi, M., Harada, M., Narabayashi,
H., Inagaki, H., Minami, M., and
Nagatsu, T. (1996). Interleukin (IL)-1
beta, IL-2, IL-4, IL-6 and transform-
ing growth factor-alpha levels are
elevated in ventricular cerebrospinal
ﬂuid in juvenile parkinsonism and
Parkinson’s disease. Neurosci. Lett.
211, 13–16.
Mogi, M., Togari, A., Tanaka, K.,
Ogawa, N., Ichinose, H., and
Nagatsu, T. (2000). Increase in level
of tumor necrosis factor-α in 6-
hydroxydopamine-lesioned striatum
in rats is suppressed by immunosup-
pressant FK506. Neurosci. Lett. 289,
165–168.
Moreland, L. W. (1998). Soluble
tumor necrosis factor receptor (p75)
fusion protein (ENBREL) as a
therapy for rheumatoid arthritis.
Rheum. Dis. Clin. North Am. 24,
579–591.
Morgan, D., Gordon, M. N., Tan,
J., Wilcock, D., and Rojiani, A.
M. (2005). Dynamic complexity of
the microglial activation response in
transgenicmodels of amyloid deposi-
tion: implications forAlzheimer ther-
apeutics. J. Neuropathol. Exp. Neurol.
64, 743–753.
Mukai, Y., Nakamura, T., Yoshioka, Y.,
Shibata, H., Abe, Y., Nomura, T.,
et al. (2009). Fast binding kinetics
and conserved 3D structure under-
lie the antagonistic activity of mutant
TNF: useful information for design-
ing artiﬁcial proteo-antagonists. J.
Biochem. 146, 167–172.
Nagatsu, T., Mogi, M., Ichinose, H.,
and Togari, A. (2000). Cytokines in
Parkinson’s disease. J. Neural Transm.
Suppl. 2000, 143–151.
Nagatsu, T., and Sawada, M. (2005).
Inﬂammatory process in Parkinson’s
disease: role for cytokines. Curr.
Pharm. Des. 11, 999–1016.
Naude, P. J., DenBoer, J.A., Luiten, P.G.,
and Eisel, U. L. (2011). Tumor necro-
sis factor receptor cross-talk. FEBS J.
278, 888–898.
Nishimura, M., Mizuta, I., Mizuta, E.,
Yamasaki, S., Ohta, M., and Kuno,
S. (2000). Inﬂuence of interleukin-
1b gene polymorphisms on age-at-
onset of sporadic Parkinson’s disease.
Neurosci. Lett. 284, 73–76.
Obeso, J. A., Rodriguez-Oroz, M. C.,
Goetz, C. G., Marin, C., Kordower, J.
H., Rodriguez,M., et al. (2010). Miss-
ing pieces in the Parkinson’s disease
puzzle. Nat. Med. 16, 653–661.
Okun, M. S. (2012). Deep-brain stimu-
lation forParkinson’s disease. N.Engl.
J. Med. 367, 1529–1538.
Old, L. J. (1985). Tumor necrosis factor
(TNF). Science 230, 630–632.
Park, H. J., Lee, P. H., Ahn, Y. W.,
Choi, Y. J., Lee, G., Lee, D. Y.,
et al. (2007). Neuroprotective effect
of nicotine on dopaminergic neurons
by anti-inﬂammatory action. Eur. J.
Neurosci. 26, 79–89.
Pascale, E., Passarelli, E., Purcaro, C.,
Vestri, A. R., Fakeri, A., Guglielmi,
R., et al. (2011). Lack of associa-
tion between IL-1beta, TNF-alpha,
and IL-10 gene polymorphisms and
sporadic Parkinson’s disease in an
Italian cohort. Acta Neurol. Scand.
124, 176–181.
Perry, V. H., Cunningham, C., and
Boche,D. (2002). Atypical inﬂamma-
tion in the central nervous system in
prion disease. Curr. Opin. Neurol. 15,
349–354.
Perry, V. H., Nicoll, J. A., and Holmes,
C. (2010). Microglia in neurodegen-
erative disease. Nat. Rev. Neurol. 6,
193–201.
Pitossi, F., Del Rey, A., Kabiersch, A.,
and Besedovsky, H. (1997). Induc-
tion of cytokine transcripts in the
central nervous system and pituitary
following peripheral administration
of endotoxin to mice. J. Neurosci. Res.
48, 287–298.
Pott Godoy, M. C., Ferrari, C. C.,
and Pitossi, F. J. (2010). Nigral neu-
rodegeneration triggered by striatal
AdIL-1 administration can be exac-
erbated by systemic IL-1 expression.
J. Neuroimmunol. 222, 29–39.
Pott Godoy, M. C., Tarelli, R., Fer-
rari, C. C., Sarchi, M. I., and Pitossi,
F. J. (2008). Central and systemic
IL-1 exacerbates neurodegeneration
and motor symptoms in a model
of Parkinson’s disease. Brain 131,
1880–1894.
Qian, J., Zhu, L., Li, Q., Belevych,
N., Chen, Q., Zhao, F., et al.
(2012). Interleukin-1R3 mediates
interleukin-1-induced potassium
current increase through fast
Frontiers in Cellular Neuroscience www.frontiersin.org April 2013 | Volume 7 | Article 53 | 9
“fncel-07-00053” — 2013/4/25 — 22:14 — page 10 — #10
Leal et al. IL-1 andTNF in Parkinson’s Disease
activation of Akt kinase. Proc.
Natl. Acad. Sci. U.S.A. 109,
12189–12194.
Rappold, P. M., and Tieu, K.
(2010). Astrocytes and therapeutics
for Parkinson’s disease. Neurothera-
peutics 7, 413–423.
Roca, V., Casabona, J. C., Radice, P.,
Murta, V., and Pitossi, F. J. (2011).
The degenerating substantia nigra as
a susceptible region for gene transfer-
mediated inﬂammation. Parkinsons
Dis. 2011, 931572.
Rossi, S., Furlan, R., De Chiara, V.,
Motta, C., Studer, V., Mori, F.,
et al. (2012). Interleukin-1beta causes
synaptic hyperexcitability in multiple
sclerosis. Ann. Neurol. 71, 76–83.
Rousselet, E., Callebert, J., Parain, K.,
Joubert, C., Hunot, S., Hartmann,
A., et al. (2002). Role of TNF-alpha
receptors in mice intoxicated with
the parkinsonian toxin MPTP. Exp.
Neurol. 177, 183–192.
Rubartelli, A., Cozzolino, F., Talio, M.,
and Sitia, R. (1990). A novel secre-
tory pathway for interleukin-1 beta,
a protein lacking a signal sequence.
EMBO J. 9, 1503–1510.
Rubio-Perez, J. M., and Morillas-Ruiz, J.
M. (2012). A review: inﬂammatory
process in Alzheimer’s disease, role
of cytokines. ScientiﬁcWorldJournal
2012, 756357.
Saijo, K., Winner, B., Carson, C. T., Col-
lier, J. G., Boyer, L., Rosenfeld, M.
G., et al. (2009). A Nurr1/CoREST
pathway in microglia and astrocytes
protects dopaminergic neurons from
inﬂammation-induced death. Cell
137, 47–59.
Saunders, B. M., Tran, S., Ruuls, S.,
Sedgwick, J. D., Briscoe, H., and
Britton, W. J. (2005). Transmem-
brane TNF is sufﬁcient to initiate
cell migration and granuloma for-
mation and provide acute, but not
long-term, control of Mycobacterium
tuberculosis infection. J. Immunol.
174, 4852–4859.
Saura, J., Pares, M., Bove, J.,
Pezzi, S., Alberch, J., Marin, C.,
et al. (2003). Intranigral infusion
of interleukin-1beta activates astro-
cytes and protects from subsequent
6-hydroxydopamine neurotoxicity. J.
Neurochem. 85, 651–661.
Schnell, L., Fearn, S., Schwab, M.
E., Perry, V. H., and Anthony, D.
C. (1999). Cytokine-induced acute
inﬂammation in the brain and spinal
cord. J. Neuropathol. Exp. Neurol. 58,
245–254.
Schumann, R. R., Belka, C., Reuter,
D., Lamping, N., Kirschning, C.
J., Weber, J. R., et al. (1998).
Lipopolysaccharide activates caspase-
1 (interleukin-1-converting enzyme)
in cultured monocytic and endothe-
lial cells. Blood 91, 577–584.
Shytle, R. D., Mori, T., Townsend, K.,
Vendrame, M., Sun, N., Zeng, J.,
et al. (2004). Cholinergic modulation
of microglial activation by alpha 7
nicotinic receptors. J. Neurochem. 89,
337–343.
Silverman, M. N., Pearce, B. D.,
Biron, C. A., and Miller, A. H.
(2005). Immune modulation of
the hypothalamic–pituitary–adrenal
(HPA) axis during viral infection.
Viral Immunol. 18, 41–78.
Smith, G. A., Isacson, O., and Dun-
nett, S. B. (2012). The search for
genetic mouse models of prodromal
Parkinson’s disease. Exp. Neurol. 237,
267–273.
Song, I. U., Chung, S. W., Kim, J. S.,
and Lee, K. S. (2011). Association
between high-sensitivity C-reactive
protein and risk of early idiopathic
Parkinson’s disease. Neurol. Sci. 32,
31–34.
Soreq, L., Israel, Z., Bergman, H.,
and Soreq, H. (2008). Advanced
microarray analysis highlights
modiﬁed neuro-immune sig-
naling in nucleated blood cells
from Parkinson’s disease patients.
J. Neuroimmunol. 201–202,
227–236.
Sriram, K., Matheson, J. M., Benkovic,
S. A., Miller, D. B., Luster, M. I., and
O’callaghan, J. P. (2002). Mice deﬁ-
cient in TNF receptors are protected
against dopaminergic neurotoxicity:
implications for Parkinson’s disease.
FASEB J. 16, 1474–1476.
Sriram, K., Matheson, J. M., Benkovic,
S. A., Miller, D. B., Luster, M.
I., and O’callaghan, J. P. (2006).
Deﬁciency of TNF receptors sup-
presses microglial activation and
alters the susceptibility of brain
regions to MPTP-induced neurotox-
icity: role of TNF-alpha. FASEB J. 20,
670–682.
Taganov, K. D., Boldin, M. P., Chang,
K. J., and Baltimore, D. (2006).
NF-kappaB-dependent induction of
microRNA miR-146, an inhibitor tar-
geted to signaling proteins of innate
immune responses. Proc. Natl. Acad.
Sci. U.S.A. 103, 12481–12486.
Tecoma, E. S., and Iragui, V. J.
(2006). Vagus nerve stimulation
use and effect in epilepsy: what
have we learned? Epilepsy Behav. 8,
127–136.
Tobinick, E. (2009). Tumour necro-
sis factor modulation for treatment
of Alzheimer’s disease: rationale and
current evidence. CNS Drugs 23,
713–725.
Torres, D., Janot, L., Quesniaux, V. F.,
Grivennikov, S. I., Maillet, I., Sedg-
wick, J. D., et al. (2005). Membrane
tumor necrosis factor confers partial
protection to Listeria infection. Am.
J. Pathol. 167, 1677–1687.
Tracey, D., Klareskog, L., Sasso, E.
H., Salfeld, J. G., and Tak, P. P.
(2008). Tumor necrosis factor antag-
onist mechanisms of action: a com-
prehensive review. Pharmacol. Ther.
117, 244–279.
Tracey, K. J. (2002). The inﬂammatory
reﬂex. Nature 420, 853–859.
Tsung, K., and Norton, J. A. (2006).
Lessons from Coley’s Toxin. Surg.
Oncol. 15, 25–28.
Turnbull, A. V., and Rivier, C. L. (1999).
Regulation of the hypothalamic–
pituitary–adrenal axis by cytokines:
actions and mechanisms of action.
Physiol. Rev. 79, 1–71.
van de Veerdonk, F. L., Netea, M. G.,
Dinarello, C. A., and Joosten, L.
A. (2011). Inﬂammasome activation
and IL-1beta and IL-18 processing
during infection. Trends Immunol.
32, 110–116.
Wahner, A. D., Sinsheimer, J. S., Bron-
stein, J. M., and Ritz, B. (2007).
Inﬂammatory cytokine gene poly-
morphisms and increased risk of
Parkinson disease. Arch. Neurol. 64,
836–840.
Wallach, D., Engelmann, H., Nophar, Y.,
Aderka, D., Kemper, O., Hornik, V.,
et al. (1991). Soluble and cell surface
receptors for tumor necrosis factor.
Agents Actions Suppl. 35, 51–57.
Weber, A., Wasiliew, P., and Kracht, M.
(2010). Interleukin-1 (IL-1) pathway.
Sci. Signal. 3, cm1.
Wirdefeldt, K., Adami, H. O., Cole,
P., Trichopoulos, D., and Mandel, J.
(2011). Epidemiology and etiology of
Parkinson’s disease: a review of the
evidence. Eur. J. Epidemiol. 26(Suppl.
1), S1–S58.
Wong, B. R., Josien, R., Lee, S. Y., Volo-
godskaia, M., Steinman, R. M., and
Choi, Y. (1998). The TRAF family
of signal transducers mediates NF-
kappaB activation by the TRANCE
receptor. J. Biol. Chem. 273, 28355–
28359.
Yoon, K., Jung, E. J., Lee, S. R., Kim,
J., Choi, Y., and Lee, S. Y. (2008).
TRAF6 deﬁciency promotes TNF-
induced cell death through inactiva-
tion of GSK3beta. Cell Death Differ.
15, 730–738.
Zalevsky, J., Secher, T., Ezhevsky, S.
A., Janot, L., Steed, P. M., O’brien,
C., et al. (2007). Dominant-negative
inhibitors of soluble TNF attenuate
experimental arthritis without sup-
pressing innate immunity to infec-
tion. J. Immunol. 179, 1872–1883.
Conflict of Interest Statement: The
authors declare that the research was
conducted in the absence of any com-
mercial or ﬁnancial relationships that
could be construed as a potential con-
ﬂict of interest.
Received: 30 January 2013; accepted: 10
April 2013; published online: 29 April
2013.
Citation: Leal MC, Casabona JC, Puntel
M and Pitossi FJ (2013) Interleukin-1β
and tumor necrosis factor-α: reliable tar-
gets for protective therapies in Parkinson’s
Disease? Front. Cell. Neurosci. 7:53. doi:
10.3389/fncel.2013.00053
Copyright © 2013 Leal, Casabona, Pun-
tel and Pitossi. This is an open-access
article distributed under the terms of the
Creative Commons Attribution License,
which permits use, distribution and
reproduction in other forums, provided
the original authors and source are cred-
ited and subject to any copyright notices
concerning any third-party graphics etc.
Frontiers in Cellular Neuroscience www.frontiersin.org April 2013 | Volume 7 | Article 53 | 10
